Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.71 |
| ▸ | CNR2 | P34972 | 1/20 | 0.71 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SCARB1 | Q8WTV0 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12669723 | 0.89 | CNR1 (0.69) | CNR1CNR2MAPK14POLBKDM4E | |
| SCHEMBL4953382 | 0.89 | CNR1 (0.69) | CNR1CNR2MAPK14POLBKDM4E | |
| SCHEMBL1600223 | 0.89 | CNR1 (0.69) | CNR1CNR2MAPK14POLBKDM4E | |
| SCHEMBL1599885 | 0.87 | CNR1 (0.67) | CNR1CNR2MAPK14SCARB1 | |
| SCHEMBL2788543 | 0.87 | CNR1 (0.72) | CNR1CNR2MAPK14POLBKDM4E | |
| SCHEMBL12669727 | 0.85 | CNR1 (0.64) | CNR1CNR2MAPK14POLBMEN1 | |
| SCHEMBL12669895 | 0.81 | MAPK14 (0.59) | CNR1CNR2MAPK14KDM4ESCARB1 | |
| SCHEMBL1600030 | 0.81 | MAPK14 (0.57) | CNR1CNR2MAPK14KDM4ESCARB1 | |
| SCHEMBL1599810 | 0.81 | MAPK14 (0.57) | CNR1CNR2MAPK14KDM4ESCARB1 | |
| SCHEMBL1600264 | 0.81 | CNR1 (0.64) | CNR1CNR2MAPK14POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011063076-A1 | METHODS OF TREATING HEPATITIS C VIRUS WITH OXOACETAMIDE COMPOUNDS | ITHERX PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063076-A1 | METHODS OF TREATING HEPATITIS C VIRUS WITH OXOACETAMIDE COMPOUNDS | ITHERX PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20110117055-A1 | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds | BRS - TUSTIN SAFEGUARD ASSOCIATES II, LLC | 2011-05-19 | — | — | US | disclosed |
| US-20110117055-A1 | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds | BRS - TUSTIN SAFEGUARD ASSOCIATES II, LLC | 2011-05-19 | — | — | US | disclosed |
| US-20110117055-A1 | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds | BRS - TUSTIN SAFEGUARD ASSOCIATES II, LLC | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117055-A1 | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds | OAT, HAVCR2, OTC | CNR1 2859/4885CNR2 2585/4885MAPK14 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.